LONDON - Ark Therapeutics Group plc has backed off from moving Vitor, its treatment for cancer cachexia, into a full-scale Phase III trial after talks with the FDA. The company instead is opting to carry out a 60-patient pilot to gather further intelligence on endpoints and consider the design of the definitive 250 patient Phase III study. (BioWorld International)

A month after disclosing positive top-line Phase II/III data with its compound for chronic myeloid leukemia (CML), ChemGenex Pharmaceuticals Ltd. is spinning out its efforts in diabetes and obesity in favor of the cancer push. (BioWorld Today)